Lead ZUMA-1 Researcher Highlights CAR T Cell Findings in NHL – OncLive
OncLive |
Lead ZUMA-1 Researcher Highlights CAR T Cell Findings in NHL
OncLive The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (KTE-C19) has shown very promising results in patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal lymphoma, and transformed follicular lymphoma. |
